Melanotan 2 (MT-II, MT2)

Comprehensive Research Analysis - Melanocortin Receptor Agonist for Tanning & Sexual Function

Classification: Cyclic Heptapeptide, Non-Selective Melanocortin Receptor Agonist, α-MSH Analog Amino Acid Sequence: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ Chemical Formula: C₅₀H₆₉N₁₅O₉ Molecular Weight: 1,024.198 Da Research Status: Failed to Complete Clinical Trials WADA Status: Prohibited (S0 - Non-Approved Substances)

1. Executive Summary

Melanotan 2 (also known as MT-II or MT2) is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) designed to activate multiple melanocortin receptors. MT-II is a potent, non-selective melanocortin ligand with agonist activity at MC1R, MC3R, MC4R, and MC5R.

Dual Primary Effects:

1. Tanning: Melanogenesis via MC1R activation
2. Sexual Function: Libido enhancement and erectile function via MC4R activation

• Serious skin cancer risk - change in mole shape, new moles, melanoma
• Rhabdomyolysis - muscle breakdown causing kidney damage
• [Systemic toxicity - kidney dysfunction, brain swelling](https://www.unsw.edu.au/newsroom/news/2023/01/what-is-melanotan-ii---

Goal Archetype Relevance (Critically Evaluate Risk vs Benefit):

• Aesthetic Optimization: Achieving melanin-rich skin pigmentation without UV exposure (melanoma risk consideration paramount)
• Sexual Health Enhancement: Libido amplification and erectile function support (primarily male application, emerging female data)
• Fat Loss Support: Appetite suppression via MC4R activation (secondary benefit, not primary indication)

the-drug-that-the-tga-urges-consumers-to-)

• Priapism - painful persistent erection requiring emergency treatment
• 38% nausea rate with 15.3% severe nausea

Regulatory Status: Melanotan II is NOT approved for general public use by major regulatory bodies (FDA, TGA). Introduction and delivery into interstate commerce violates federal law. Sale for human use is illegal in many jurisdictions.

2. First Principles - Melanocortin Receptor Agonism & Alpha-MSH Biology

2.1 The Endogenous Melanocortin System

Proopiomelanocortin (POMC) - The Master Precursor:

POMC is a 241-amino-acid precursor polypeptide synthesized in corticotrophs of the anterior pituitary, hypothalamus, and peripherally in skin keratinocytes and melanocytes. POMC processing produces many biologically active peptides via tissue-specific enzymatic cleavage, yielding melanocyte-stimulating hormones (α-MSH, β-MSH, γ-MSH), corticotrophin (ACTH), and beta-endorphin.

Alpha-MSH (α-Melanocyte-Stimulating Hormone):

α-MSH is a 13-amino-acid neuropeptide secreted by melanocytes and keratinocytes after ultraviolet light exposure and is the most important melanocortin for pigmentation. α-MSH acts as an anorexigenic peptide via melanocortin receptors MC3R and MC4R, inhibiting food intake and increasing energy expenditure.

Melanocortin Receptor Family:

Five melanocortin receptors (MC1R through MC5R) are seven-transmembrane G-protein-coupled receptors (GPCRs) that mediate POMC-derived peptide actions. The endogenous agonists of melanocortin receptors include α-MSH, β-MSH, γ-MSH, and ACTH.

Receptor Distribution and Primary Functions:

MC1R, MC3R, MC4R, and MC5R are widely expressed in both central nervous system and peripheral tissues, while MC2R is specific to the adrenal cortex and responds exclusively to ACTH.

Clinical Significance of Endogenous System:

Mutations in the POMC gene co-segregate with obesity phenotype in humans, emphasizing the importance of melanocortin neurons in metabolic control. Mutations in MC4R underlie the most common monogenic obesity in humans.

2.2 Melanotan-2: A Superpotent Non-Selective Agonist

Structural Design and Rationale:

Melanotan-2 is a synthetic cyclic heptapeptide analog of α-MSH with the structure Ac-Nle4-Asp5-His6-D-Phe7-Arg8-Trp9-Lys10-NH2, containing a lactam ring between the Asp and Lys residues.

Key Structural Features:

1. Cyclization: The lactam ring structure provides enhanced in vivo stability (T1/2: 1-2 hours) and blood-brain barrier permeability
2. D-Phenylalanine: Non-natural D-amino acid at position 7 confers resistance to peptidase degradation
3. Norleucine Substitution: At position 4 enhances metabolic stability vs. natural Met residue
4. N-terminal Acetylation and C-terminal Amidation: Both modifications prevent exopeptidase degradation

Blood-Brain Barrier Permeability:

Because melanotan-2 can cross the blood-brain barrier due to its cyclic structure, it activates melanocortin receptors in the CNS, enabling central effects on appetite, sexual function, and energy homeostasis that linear α-MSH cannot achieve.

Receptor Binding Profile (Ki Values):

Melanotan-2 acts as a non-selective agonist of melanocortin receptors with the following binding affinities:

• MC1R: Ki = 0.67 nM (HIGHEST affinity - 10x stronger than MC4R)
• MC4R: Ki = 6.6 nM (secondary affinity - CNS effects)
• MC3R: Ki = 34 nM (tertiary affinity - metabolic effects)
• MC5R: Ki = 46 nM (quaternary affinity - exocrine effects)
• MC2R: Minimal activity (ACTH-selective receptor largely spared)

Comparative Potency:

Compared to endogenous α-MSH, MT-II exhibits:

• ~1000-fold greater potency at MC1R (superpotent melanogenesis)
• ~100-fold greater metabolic stability (2-hour half-life vs. minutes for α-MSH)
• Enhanced lipophilicity (BBB penetration vs. α-MSH's impermeability)

2.3 MC1R Activation - Melanogenesis Cascade

Receptor Mechanism:

MC1R is a melanocytic Gs-protein-coupled receptor that regulates skin pigmentation, UV responses, and melanoma risk through adenylyl cyclase activation and cAMP generation.

Detailed Melanogenesis Pathway:

1. Ligand Binding: α-MSH (or MT-II) binds to MC1R on melanocyte surface
2. G-Protein Activation: Gs-protein activation stimulates adenylyl cyclase
3. cAMP Generation: Intracellular cAMP concentration increases
4. PKA Activation: Protein kinase A (PKA) activated by cAMP
5. CREB Phosphorylation: PKA catalytic subunit translocates to nucleus and phosphorylates CREB transcription factors
6. MITF Upregulation: Phosphorylated CREB increases transcription of MITF (Microphthalmia-associated Transcription Factor)
7. Melanogenic Enzyme Expression: MITF increases expression of tyrosinase, TYRP1, and TYRP2 (DCT)
8. Eumelanin Synthesis: Tyrosinase converts tyrosine → DOPA → dopaquinone → eumelanin (brown-black pigment)

Eumelanin vs. Pheomelanin:

MC1R activation promotes eumelanin (brown-to-black pigment that effectively absorbs UV rays) synthesis over pheomelanin (red-yellow pigment with poor UV protection). Brown/black eumelanin is an effective filter against ultraviolet radiation and a scavenger of free radicals.

Photoprotection Mechanism:

Activation of cAMP signaling upregulates melanin production and deposition in the epidermis, which functions to limit UV penetration into the skin. Eumelanin confers photoprotection from solar UV radiation by absorbing and scattering UV photons.

Additional MC1R Functions (Beyond Pigmentation):

α-MSH binding to MC1R activates not only melanogenesis but also melanocytic proliferation, survival, and migration. MC1R activation on leukocytes promotes anti-inflammatory signaling.

2.4 MC4R Activation - Sexual Arousal & Appetite Suppression

MC4R CNS Distribution:

MC4R expression is found in the paraventricular nucleus (PVN) of the hypothalamus, brainstem, spinal cord (sacral segments S2-S4), and pelvic ganglion (autonomic relay center to the penis). MC4R-controlled neuronal pathways regulate sexual function and energy homeostasis.

Sexual Arousal Cascade (Central Mechanism):

1. BBB Penetration: MT-II crosses blood-brain barrier (lipophilic cyclic peptide)
2. MC4R Binding: MT-II activates MC4R in paraventricular nucleus (PVN) of hypothalamus
3. Oxytocin Release: MC4R activation stimulates oxytocin-releasing neurons in PVN
4. Spinal Projection: Oxytocin neurons project to spinal cord (sacral segments S2-S4)
5. Parasympathetic Outflow: Activation of parasympathetic outflow to genital arteries
6. Nitric Oxide Release: NO released from endothelial cells and nerves
7. cGMP Generation: NO activates guanylate cyclase → cGMP accumulation
8. Smooth Muscle Relaxation: cGMP causes arterial and trabecular smooth muscle relaxation
9. Erection/Engorgement: Increased blood flow to erectile tissues (penis/clitoris)

Clinical Evidence - Male Sexual Function:

In a double-blind crossover study (N=20 men with psychogenic and organic ED), MC4R agonism with 0.025 mg/kg MT-II produced penile erection in 17/20 (85%) subjects. MC4R agonists are effective for both psychogenic ED (CNS-mediated pathway intact) and organic ED (neural pathway bypasses some vascular limitations).

Clinical Evidence - Female Sexual Function (2022-2024 Data):

In women with hypoactive sexual desire disorder (HSDD), MC4R agonism significantly increased sexual desire for up to 24 hours compared with placebo. During functional neuroimaging, MC4R agonism enhanced cerebellar and supplementary motor area activity and deactivated secondary somatosensory cortex specifically in response to visual erotic stimuli. MC4R agonism enhanced functional connectivity between amygdala and insula during erotic stimuli, reducing self-consciousness and increasing sexual imagery.

Appetite Suppression Mechanism:

MC4R activation in the hypothalamus (arcuate nucleus and paraventricular nucleus) mediates anorexigenic effects by counteracting orexigenic AgRP (agouti-related peptide) signaling. α-MSH (and MT-II) acts as an anorexigenic peptide via MC4R, inhibiting food intake and increasing energy expenditure.

Dose-Dependent Effects:

• Low Dose (0.25-0.5 mg): Mild appetite suppression, minimal sexual effects
• Moderate Dose (0.5-1.0 mg): Balanced appetite suppression + sexual arousal
• High Dose (1.0-1.5 mg): Strong sexual arousal, significant spontaneous erections, intense appetite suppression

2.5 MC3R and MC5R - Secondary Effects

MC3R (Melanocortin-3 Receptor):

MC3R is predominantly expressed in the hypothalamus (arcuate nucleus, ventromedial hypothalamus) and peripherally in placenta, gut, and heart. MC3R is involved in energy balance, metabolism, and appetite regulation. MC3R and MC4R function independently, playing complementary rather than redundant roles in energy control.

MC3R Functions with MT-II:

• Contributes to appetite suppression (synergistic with MC4R)
• May modulate sexual arousal (secondary to MC4R)
• Cardiovascular regulation (peripheral expression in heart)
• Immune response modulation

MC5R (Melanocortin-5 Receptor):

MC5R is widely expressed in exocrine glands, skin, adipose tissue, skeletal muscle, kidney, liver, and brain. MC5R is the predominant subtype expressed in skeletal muscle and white adipose tissue. MC5R activation triggers lipid mobilization in adipocytes and glucose uptake in skeletal muscle.

MC5R Functions with MT-II:

• Sebaceous gland lipid production (potential for facial flushing)
• Exocrine function modulation
• Mild lipolytic effects (fat mobilization)
• Glucose uptake enhancement in skeletal muscle
• Immune and inflammatory response modulation

Clinical Significance:

MT-II's activation of MC3R and MC5R contributes to side effect profile:

• Flushing: MC5R activation in sebaceous/eccrine glands
• Nausea: MC3R/MC4R activation in hypothalamic areas
• Yawning: MC3R/MC4R CNS effects
• Mild Lipolysis: MC5R adipose tissue activation (minor fat loss effect)

2.6 Why MT-II is "Non-Selective" (And Why This Matters)

Selectivity Profile Comparison:

Consequences of Non-Selectivity:

1. Therapeutic Versatility: MT-II can address multiple goals (tanning + sexual function + mild appetite suppression)
2. Unpredictable Side Effect Profile: Activating all receptors simultaneously produces wide-ranging effects
3. Dose-Dependent Effect Hierarchy: Lower doses favor MC1R (highest affinity); higher doses recruit MC4R, MC3R, MC5R
4. Safety Concerns: Cannot isolate desired effect from undesired effects (e.g., cannot get tanning without some sexual arousal)

Why Selective Agonists Were Developed:

• Afamelanotide (Scenesse): MC1R-selective for erythropoietic protoporphyria (photoprotection without sexual side effects)
• Bremelanotide (Vyleesi): MC4R-selective for female HSDD (sexual arousal without tanning or severe nausea)

MT-II's failure to complete clinical trials was partly due to inability to separate therapeutic effects from adverse effects due to non-selective receptor activation.

2.7 First Principles Summary: Why MT-II Works (And Why It's Risky)

Fundamental Mechanism:

Melanotan-2 is a superpotent, metabolically stable, BBB-penetrant, non-selective melanocortin receptor agonist that hijacks the endogenous POMC/melanocortin system to produce:

1. Melanogenesis (MC1R): 1000x more potent than α-MSH at stimulating eumelanin production
2. Sexual Arousal (MC4R): Central mechanism bypassing peripheral vascular pathways
3. Appetite Suppression (MC4R/MC3R): Hypothalamic satiety signaling activation
4. Systemic Effects (MC3R/MC5R): Cardiovascular, metabolic, immune, exocrine effects

Why It's Effective:

• Pharmacokinetic Optimization: Cyclic structure confers stability, BBB permeability, peptidase resistance
• Superpotent Receptor Activation: Nanomolar affinity at MC1R and MC4R
• Dual Primary Effects: Unique ability to simultaneously tan and enhance libido

Why It's Dangerous:

• Non-Selective Activation: Cannot isolate desired effects from adverse effects
• MC1R Overstimulation Risk: Uncontrolled melanocyte proliferation → melanoma concern
• Systemic Toxicity: Rhabdomyolysis, kidney dysfunction, cardiovascular effects
• Lack of Clinical Validation: Failed to complete Phase III trials; no long-term safety data

Critical Insight:

MT-II's mechanism is sound and well-understood. The melanocortin system is a validated therapeutic target (afamelanotide and bremelanotide are FDA-approved). The problem is non-selectivity and lack of controlled clinical development, not the underlying pharmacology.

3. Goal Archetype Integration

MT-II addresses three distinct optimization archetypes through its non-selective melanocortin receptor agonism. CRITICAL CONSIDERATION: Given the serious safety profile (melanoma risk, rhabdomyolysis, systemic toxicity), the risk-benefit analysis must be extraordinarily stringent for ANY application.

3.1 Aesthetic Optimization - Melanin Production

Primary Application: Achieving darker skin pigmentation without UV exposure or with reduced UV requirement.

Mechanism Alignment:

• MC1R activation (Ki = 0.67 nM, highest affinity receptor)
• Stimulates melanocyte melanin synthesis (eumelanin production)
• Darkens existing melanin, increases melanocyte activity, expands melanin distribution
• Effect visible within 3-5 doses; full pigmentation typically 2-4 weeks

Target Outcomes:

• 3-5 shade deepening of baseline skin tone (Fitzpatrick scale shift)
• Enhanced UV protection from increased melanin (natural SPF 2-4 equivalent)
• More even pigmentation distribution (reduced patchiness vs natural tanning)
• Persistent pigmentation 4-8 weeks post-discontinuation

Protocol Recommendation:

• Loading Phase: 0.25-0.5 mg daily for 7-10 days (assess nausea tolerance)
• Loading Phase (continued): 0.5-1.0 mg daily for 10-14 days (pigmentation development)
• Maintenance Phase: 0.5-1.0 mg every 2-3 days (maintain desired pigmentation)
• UV Exposure Timing: 2-4 hours post-injection (peak melanocyte activity)
• UV Exposure Recommendation: Minimal (10-15 min) vs natural tanning (30-60 min) for equivalent pigmentation

CRITICAL SAFETY CONSIDERATION - MELANOMA RISK:

• Any individual with personal or family history of melanoma: ABSOLUTE CONTRAINDICATION
• Fitzpatrick Skin Type I-II (very fair skin): HIGHEST RISK - avoid unless benefit extraordinarily outweighs risk
• >10 moles or atypical moles: CONTRAINDICATION
• Required Monitoring: Full-body dermatological examination BEFORE starting, monthly self-checks, professional skin check every 3-6 months during use
• STOP IMMEDIATELY if any mole changes size, shape, color, or bleeds

Who Should NOT Use MT-II for Tanning:

• Personal or family history of melanoma or skin cancer

• 10 moles or dysplastic nevus syndrome

• Immunosuppression
• Age <21 (incomplete melanocyte development)
• Pregnancy or breastfeeding
• Inability to access regular dermatological monitoring

Safer Alternatives to Consider First:

• Dihydroxyacetone (DHA) spray tans or lotions (topical, no systemic risk)
• Gradual sun exposure with SPF protection
• Acceptance of natural skin tone

3.2 Sexual Health Enhancement - Libido and Erectile Function

Primary Application: Enhancing sexual desire (libido) and erectile function, particularly in men with psychogenic or organic erectile dysfunction.

Mechanism Alignment:

• MC4R activation (Ki = 6.6 nM) in central nervous system
• MC3R activation (Ki = 34 nM) contributing to sexual arousal
• CNS-mediated erection pathway (distinct from PDE5 inhibitors like Viagra)
• Acts on hypothalamic and spinal melanocortin circuits

Clinical Evidence:

• Double-blind crossover (N=20 men): 17/20 (85%) achieved erection at 0.025 mg/kg
• Effective for both psychogenic AND organic ED (unlike PDE5 inhibitors, which primarily address organic ED)
• Onset: 2-6 hours post-injection
• Duration: 6-12 hours (individual variation)

Target Outcomes:

• Enhanced libido and sexual desire (mental arousal)
• Improved erectile rigidity and duration
• Spontaneous erections (common side effect, can be positive or negative depending on context)
• Potential benefit for female sexual arousal (limited data, see sex-specific section)

Protocol Recommendation (Male):

• Dose: 0.5-1.5 mg administered 2-6 hours before anticipated sexual activity
• Frequency: As-needed dosing (not daily) to minimize tachyphylaxis and side effects
• Timing: Empty stomach administration reduces nausea
• Nausea Mitigation: Start at 0.5 mg to assess tolerance; antihistamine 30 min prior may help

Protocol Recommendation (Female - VERY LIMITED DATA):

• Dose: 0.25-0.5 mg (lower than male dosing due to smaller body mass and heightened sensitivity)
• Expected Effects: Increased genital arousal, enhanced desire, vaginal lubrication
• Data Limitation: Most clinical trials excluded women; dosing extrapolated from male studies

Sex-Specific Considerations (Detailed in Section 7):

• Men: More robust clinical data; erection as measurable endpoint
• Women: Very limited clinical trials; self-reported arousal as primary endpoint; anecdotal reports suggest efficacy but no controlled studies

Comparative Pharmacology:

Combination Potential:

• MT-II + PDE5 inhibitor theoretically synergistic (central + peripheral pathways)
• CAUTION: No clinical trials evaluating safety of combination
• Risk of priapism may be elevated with combination
• If combining, use lowest effective dose of each

Who Should NOT Use MT-II for Sexual Enhancement:

• History of priapism (ABSOLUTE CONTRAINDICATION)
• Sickle cell disease, leukemia, or multiple myeloma (priapism risk)
• Anatomical deformation of penis (Peyronie's disease if severe)
• Current use of alpha-blockers (hypotension risk)

3.3 Fat Loss Support - Appetite Suppression and Lipolysis

Primary Application: Appetite suppression as adjunct to fat loss protocol (NOT a primary fat loss agent).

Mechanism Alignment:

• MC4R activation in hypothalamus (appetite regulation center)
• Reduces food intake via melanocortin-mediated satiety signaling
• Possible enhancement of lipolysis (fat breakdown) via MC5R (weaker evidence)
• Effect magnitude: Mild to moderate appetite suppression

Clinical Evidence:

• Phase I trial: "Decreased appetite" commonly reported
• No controlled trials specifically evaluating MT-II for weight loss
• Appetite suppression is a SIDE EFFECT, not a primary studied endpoint
• Effect diminishes with continued use (tachyphylaxis)

Target Outcomes:

• Reduced caloric intake (10-20% reduction reported anecdotally)
• Easier adherence to caloric deficit
• Possible mild increase in energy expenditure (weak evidence)

Protocol Recommendation:

• Dose: 0.5-1.0 mg administered before largest meal or in morning
• Expectation Management: This is NOT a GLP-1 agonist; appetite suppression is MUCH weaker than semaglutide/tirzepatide
• Tachyphylaxis: Effect diminishes within 2-4 weeks of daily use
• Cycling: Use intermittently (e.g., 2 weeks on, 1 week off) to preserve appetite effect

Comparative Pharmacology (Appetite Suppression):

CRITICAL ASSESSMENT: Given the serious safety risks of MT-II (melanoma, rhabdomyolysis, systemic toxicity) and the availability of FDA-approved GLP-1 agonists with superior appetite suppression and favorable safety profiles, MT-II should NOT be used primarily for fat loss. If appetite suppression is the goal, GLP-1 agonists are vastly superior and safer.

Fat Loss Protocol Integration (If Already Using MT-II for Tanning/Libido):

• If using MT-II for primary indications (tanning or sexual health), appetite suppression may be a beneficial secondary effect
• Do not initiate MT-II solely for fat loss purposes
• If appetite suppression occurs, leverage it: time injection before largest meal, use to support caloric deficit

3.4 Longevity and Anti-Aging Pathways

Primary Application: Theoretical melanocortin-mediated anti-aging effects (NO clinical validation for longevity).

Mechanism Alignment:

• MC1R activation → UV photoprotection via melanin (reduces cumulative UV-induced skin aging and DNA damage)
• MC3R/MC4R activation → metabolic regulation, energy homeostasis (theoretical anti-aging via metabolic optimization)
• MC1R anti-inflammatory signaling → potential reduction in chronic inflammation (theoretical)

Scientific Evidence for Longevity Effects:

• UV Protection: Eumelanin confers photoprotection from solar UV radiation, limiting DNA damage accumulation. Reduced UV-induced DNA damage theoretically reduces cancer risk and premature aging.
• Melanocortin System & Aging: POMC/melanocortin system regulates energy balance and metabolic homeostasis, which are linked to lifespan in model organisms. However, NO human longevity data exists for MT-II.
• MC1R Anti-Inflammatory Effects: MC1R activation on leukocytes promotes anti-inflammatory signaling, potentially reducing chronic inflammation (a hallmark of aging).

Target Outcomes (Theoretical):

• Reduced cumulative UV-induced DNA damage (via enhanced melanin photoprotection)
• Reduced oxidative stress from UV exposure
• Possible metabolic optimization via MC4R (appetite regulation, energy expenditure)
• Potential reduction in chronic low-grade inflammation

Critical Assessment - Longevity Application:

MAJOR PROBLEM: Melanoma Risk Negates Any Longevity Benefit

The primary proposed longevity mechanism (UV photoprotection via melanin) is completely negated by MT-II's serious melanoma risk. Key issues:

1. MC1R Overstimulation Risk: Uncontrolled melanocyte proliferation may increase melanoma risk
2. New Mole Formation: MT-II can cause new moles and changes in existing moles
3. No Long-Term Safety Data: MT-II failed clinical trials; no data on 10+ year safety
4. Risk > Benefit: Even if UV protection provides minor longevity benefit, melanoma risk far outweighs this

Metabolic/Anti-Inflammatory Pathways:

• MC4R metabolic effects are MILD (not comparable to proven longevity interventions)
• No evidence MT-II extends lifespan in any model organism
• Anti-inflammatory effects of MC1R are theoretical in humans

Comparison to Proven Longevity Interventions:

Longevity Protocol Recommendation: DO NOT USE MT-II FOR LONGEVITY PURPOSES

Rationale:

1. No evidence of lifespan extension in any organism
2. Melanoma risk negates any theoretical UV protection benefit
3. Serious adverse events (rhabdomyolysis, systemic toxicity) inconsistent with longevity optimization
4. Vastly superior alternatives exist with established safety profiles

Safer Longevity-Focused Alternatives:

• Sun Protection: SPF 30-50 sunscreen daily (proven skin cancer prevention, zero systemic risk)
• Metabolic Optimization: Metformin (if pre-diabetic), caloric restriction, exercise
• Anti-Inflammatory: Omega-3 fatty acids, Mediterranean diet, regular exercise
• Proven Interventions: Rapamycin (if willing to accept immunosuppression risk), senolytics (emerging)

Verdict: MT-II has NO ROLE in evidence-based longevity protocols. Risk profile is incompatible with life extension goals.

3.5 Cognitive Enhancement

Primary Application: Theoretical melanocortin receptor effects on cognitive function (NO clinical validation).

Mechanism Alignment:

• MC4R CNS Expression: MC4R expressed in hippocampus, amygdala, cortex (brain regions involved in memory, emotion, cognition)
• MC3R/MC4R Metabolic Effects: Energy homeostasis regulation may indirectly affect cognitive function
• BBB Permeability: MT-II crosses blood-brain barrier, enabling CNS effects

Scientific Evidence for Cognitive Effects:

• Animal Studies: Melanocortin receptor agonists modulate learning and memory in rodent models (no human data)
• MC4R & Cognition: MC4R activation affects energy balance and feeding behavior, which indirectly influences cognitive performance via metabolic state
• NO HUMAN COGNITIVE TRIALS: Zero clinical trials evaluating MT-II's effects on memory, focus, processing speed, or any cognitive domain

Theoretical Cognitive Effects:

• Enhanced focus via appetite suppression (reduced postprandial cognitive decline)
• Possible modulation of arousal/attention via CNS melanocortin signaling
• Indirect cognitive benefit from metabolic optimization (weak rationale)

Critical Assessment - Cognitive Enhancement Application:

PROBLEM: No Evidence + Serious Safety Risks

1. Zero Human Data: No clinical trials, case reports, or systematic anecdotal evidence of cognitive enhancement
2. Mechanism Unclear: Melanocortin receptors in brain primarily regulate feeding/sexual behavior, NOT cognition
3. Side Effect Profile Impairs Cognition:
   • Nausea (38% incidence): Severe nausea impairs cognitive function
   • Flushing, Yawning: Distracting autonomic effects
   • Sexual Arousal: Spontaneous erections/arousal distracting for cognitive tasks
4. Safety Risks Outweigh Speculative Benefit: Melanoma risk, rhabdomyolysis, systemic toxicity

Comparison to Proven Cognitive Enhancers:

Cognitive Enhancement Protocol Recommendation: DO NOT USE MT-II FOR COGNITIVE PURPOSES

Rationale:

1. Zero evidence of cognitive enhancement in humans
2. Side effects (nausea, flushing, sexual arousal) likely impair rather than enhance cognition
3. Serious safety risks incompatible with cognitive optimization goals
4. Vastly superior alternatives with established efficacy and safety

Evidence-Based Cognitive Enhancement Alternatives:

• Acute Performance: Caffeine (100-200 mg) + L-theanine (200 mg)
• Sustained Wakefulness: Modafinil (100-200 mg, prescription required)
• Long-Term Brain Health: Omega-3 fatty acids (1-2 g EPA+DHA daily), regular exercise, sleep optimization
• Working Memory: Creatine monohydrate (5 g daily), especially during sleep deprivation

Verdict: MT-II has NO ROLE in evidence-based cognitive enhancement protocols.

3.6 Hormone Optimization

Primary Application: Indirect effects on hormonal pathways via melanocortin receptor activation (NOT a primary hormonal agent).

Mechanism Alignment:

• MC2R (ACTH Receptor): MT-II has minimal activity at MC2R, so minimal direct cortisol/ACTH effects
• MC4R Sexual Function: Enhances libido/arousal, which may reflect modulation of sex hormone pathways
• Melanocortin-Testosterone Interaction: MC4R sensitivity may be modulated by testosterone levels
• NO Direct Hormonal Effects: MT-II does NOT increase testosterone, estrogen, thyroid hormones, or growth hormone

Scientific Evidence for Hormonal Effects:

• Testosterone Interaction: Age-related testosterone decline may reduce MC4R responsiveness; MT-II sexual effects may be enhanced by adequate testosterone
• Estrogen/MC1R: Estrogen enhances melanocyte activity, potentially synergizing with MT-II for tanning
• NO Hormonal Clinical Trials: Zero studies evaluating MT-II's effects on testosterone, estrogen, cortisol, thyroid, or GH levels

Theoretical Hormonal Effects:

• Libido Enhancement: May mimic or complement effects of optimized testosterone (via MC4R CNS pathway)
• Metabolic Effects: MC4R-mediated appetite/energy regulation may indirectly affect insulin sensitivity
• No Direct Hormone Production: MT-II does NOT stimulate endocrine glands to produce hormones

Clinical Context - Hormone Optimization:

MT-II is NOT a Hormone Replacement or Optimization Agent

1. Does NOT Replace Testosterone: MT-II enhances libido via MC4R (CNS pathway), but does NOT increase testosterone levels
2. Does NOT Replace Estrogen: No effect on estrogen production; estrogen may modulate MT-II's tanning effects
3. Does NOT Affect Thyroid: No impact on T3/T4 production or thyroid function
4. Does NOT Stimulate Growth Hormone: No effect on GH/IGF-1 axis
5. Does NOT Optimize Cortisol: Minimal MC2R activity; no meaningful ACTH/cortisol modulation

Synergy with Hormone Optimization:

MT-II may be adjunctive to hormone optimization protocols (NOT a replacement):

Testosterone Replacement Therapy (TRT) + MT-II:

• Synergistic for Sexual Function: TRT provides peripheral androgenic support; MT-II activates central MC4R pathways
• Enhanced Libido: Combined effect may be greater than either alone
• Safety Consideration: Monitor hematocrit (TRT increases RBCs; MT-II-induced dehydration from nausea could concentrate blood)
• Verdict: Safe to combine for sexual function enhancement (if MT-II's serious risks are accepted)

Estrogen Replacement Therapy (ERT) + MT-II:

• Tanning Synergy: Estrogen enhances melanocyte activity; may increase MT-II tanning response
• Sexual Function (Women): Very limited data; estrogen + MT-II may synergize for female sexual arousal
• Safety Consideration: Melanoma risk may be higher in women (estrogen-melanocyte interaction)
• Verdict: Theoretical synergy, but no clinical data; melanoma risk remains prohibitive

Thyroid Optimization + MT-II:

• No Interaction: Levothyroxine + MT-II safe to combine (see Drug Interactions section)
• No Synergy: Independent pathways; no enhanced effect

Growth Hormone Optimization + MT-II:

• Common Combination: Many users combine MT-II (tanning) with GH peptides (body composition)
• No Pharmacological Interaction: Different mechanisms; safe to combine
• Practical Use: MT-II for aesthetic (tanning), GH peptides for anabolic effects

Hormone Optimization Protocol Recommendation:

MT-II is NOT a Primary Hormone Optimization Agent

Use MT-II only if:

1. Already optimizing hormones through proven methods (TRT, ERT, thyroid replacement)
2. Seeking adjunctive sexual function enhancement (MT-II's primary validated effect)
3. Accepting serious safety risks (melanoma, rhabdomyolysis) for this adjunctive benefit

Evidence-Based Hormone Optimization (Without MT-II):

• Testosterone Optimization (Men): TRT (if hypogonadal), resistance training, sleep optimization, zinc/magnesium
• Estrogen/Progesterone Optimization (Women): HRT (if menopausal), lifestyle factors
• Thyroid Optimization: Levothyroxine (if hypothyroid), selenium, iodine sufficiency
• Growth Hormone Optimization: Quality sleep, resistance training, GH peptides (ipamorelin, CJC-1295) if suboptimal
• Cortisol Optimization: Stress management, sleep hygiene, adaptogenic herbs (ashwagandha, rhodiola)

Verdict: MT-II has LIMITED ROLE as an adjunct to hormone optimization, ONLY for sexual function enhancement in individuals already on TRT/ERT. NOT a primary hormone optimization tool.

3.7 Archetype Summary Table (Complete)

Key Takeaway: MT-II is a high-risk compound with NO FDA approval and serious documented adverse events (melanoma, rhabdomyolysis, priapism, systemic toxicity). Use should be limited to informed individuals who:

1. Have exhausted safer alternatives
2. Accept the risk profile with full understanding
3. Have access to comprehensive medical monitoring (dermatology, bloodwork)
4. Have no contraindications (melanoma history, >10 moles, priapism history)

PRIMARY VALIDATED APPLICATIONS: Tanning (MC1R) and sexual function (MC4R). All other applications lack evidence and carry unacceptable risk-benefit ratios.

4. Chemical Structure & Composition

Molecular Weight: 1,024.198 Da Formula: C₅₀H₆₉N₁₅O₉ CAS Number: 121062-08-6 PubChem CID: 92432

Amino Acid Sequence

Linear Sequence Before Cyclization: Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂

Detailed Structure: Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)

Position Components:

• Ac- = N-terminal acetylation
• Nle = Norleucine
• c[...] = Cyclic structure
• D-Phe = D-phenylalanine (non-natural D-amino acid)
• -NH₂ = C-terminal amidation

Structural Characteristics

Cyclic Peptide: MT2 is a cyclic peptide - amino acid chain looped back on itself forming a ring. ε-amino group of lysine and γ-carboxy group of aspartic acid undergo carbodiimide-mediated lactamization, creating cyclic structure.

Blood-Brain Barrier Permeability: Cyclic structure provides BBB permeability, distinguishing it from linear Melanotan I.

Design Rationale: Cyclization enhances stability, reduces degradation, and improves receptor selectivity vs linear α-MSH.

5. Pharmacokinetics & Metabolism

5.1 Absorption

Route of Administration:

Subcutaneous (SC) injection is the required route for MT-II therapeutic effect. Oral administration of melanocortin peptides results in no detectable drug levels due to rapid gastrointestinal degradation.

Why Oral Administration Fails:

Most cyclic peptides cannot be applied orally because they are rapidly digested and/or display low absorption in the gastrointestinal tract. Poor oral bioavailability for most peptides is between 1-2%.

Subcutaneous Bioavailability:

Data from the structurally related Melanotan-I shows SC dosing is completely bioavailable compared to IV dosing, making subcutaneous injection highly efficient. Subcutaneous administration allows for less hindered uptake compared to oral administration and therefore higher bioavailability.

Absorption Kinetics:

Plasma half-lives following SC dosing ranged from 0.07 to 0.79 hours for the absorption phase (melanotan-I data; MT-II likely similar). Peak plasma concentration (Tmax) typically occurs 1-2 hours post-injection.

Injection Site Considerations:

• Abdomen: Fastest absorption (rich capillary network)
• Thigh: Moderate absorption (larger volume capacity)
• Gluteal: Slower absorption (deeper adipose tissue)

Effect on Absorption:

• Body Fat Percentage: Higher body fat may slow absorption slightly but does not significantly reduce bioavailability
• Injection Depth: True SC injection (not intramuscular) provides optimal absorption
• Injection Volume: Smaller volumes (0.2-0.5 mL) absorbed more rapidly than larger volumes

5.2 Distribution

Volume of Distribution:

Specific volume of distribution (Vd) data for MT-II in humans is not published. Based on peptide characteristics:

• Estimated Vd: 0.3-0.5 L/kg (moderate distribution)
• Plasma Protein Binding: Low (cyclic peptides typically <30% bound)
• Tissue Penetration: Wide distribution due to lipophilic cyclic structure

Blood-Brain Barrier (BBB) Penetration:

MT-II crosses the blood-brain barrier due to its lipophilic cyclic structure, a critical feature enabling CNS effects (sexual arousal, appetite suppression). This distinguishes MT-II from linear α-MSH, which cannot cross the BBB.

Tissue Distribution:

Animal studies demonstrate MT-II distributes to:

1. Skin (Melanocytes): Primary site of action for tanning (MC1R-rich tissue)
2. CNS (Hypothalamus, Brainstem): MC4R-rich regions for sexual and appetite effects
3. Adipose Tissue: MT-II reduces both visceral and subcutaneous adipose tissue, demonstrating penetration into fat depots
4. Muscle: Minimal accumulation; MC5R-mediated glucose uptake effects
5. Kidney: Primary elimination route; renal tissue exposure contributes to nephrotoxicity risk

Adipose Tissue Effects:

MT-II treatment led to general reduction in both visceral and subcutaneous adipose tissue in mice. Retroperitoneal white adipose tissue mass was reduced 46.3% and epididymal WAT mass reduced 21.1%, showing differential depot-specific effects.

Cyclic Structure Advantage:

Cyclic peptides exhibit superior drug-like properties, including enhanced conformational rigidity, elimination of unstable terminal residues, intramolecular hydrogen bonding, lower polarity, and enhanced metabolic stability, all contributing to MT-II's favorable distribution profile.

5.3 Metabolism

Primary Metabolic Pathways:

MT-II is metabolized by peptidases (proteolytic enzymes), NOT by hepatic cytochrome P450 enzymes. This distinction is critical for understanding drug interactions.

Peptidase Degradation:

The major sites of proteolytic degradation of peptides are the kidney and liver, where proteolytic enzymes are found in high concentrations. Specific peptidases involved in melanocortin peptide degradation include:

• Neprilysin (NEP): Abundantly present on renal membranes
• Dipeptidyl peptidase IV (DPPIV)
• Aminopeptidases
• Carboxypeptidases

Metabolic Stability Features:

MT-II's structure confers resistance to rapid degradation:

1. Cyclization: Protects from exopeptidase cleavage (no free N- or C-terminus)
2. D-Phenylalanine: Non-natural amino acid at position 7 resists peptidase recognition
3. N-acetylation: Prevents aminopeptidase attack
4. C-amidation: Prevents carboxypeptidase attack

Result: Enhanced in vivo stability with half-life of 1-2 hours, compared to minutes for linear α-MSH.

Metabolites:

Specific metabolite structures for MT-II are not well-characterized in literature. Presumed metabolites include:

• Linearized peptide fragments (after lactam ring cleavage)
• Smaller peptide fragments (after endopeptidase cleavage)
• Individual amino acids (terminal degradation products)

Pharmacological Activity of Metabolites:

No data suggests MT-II metabolites retain melanocortin receptor agonist activity. All therapeutic effects attributed to intact cyclic MT-II molecule.

5.4 Elimination

Half-Life:

MT-II exhibits a half-life of 1-2 hours (beta-phase elimination). Some sources report conflicting data (up to 33 hours), but scientific literature consistently supports the 1-2 hour range.

Elimination Phase Half-Life Data (Melanotan-I as reference):

Plasma half-lives following SC dosing ranged from 0.8 to 1.7 hours for the beta-phase. MT-II likely exhibits similar kinetics given structural similarity.

Primary Elimination Route:

Renal (Kidney): 3.9% or less of the MT-II dose was recovered unchanged in urine (melanotan-I data), indicating most drug is metabolized before urinary excretion.

Clearance:

Clearance ranged from 0.12 to 0.19 L/kg/h for the related peptide melanotan-I. This moderate clearance rate allows for once-daily dosing during loading phases.

Renal Toxicity Concern:

MT-II can cause renal infarction and kidney dysfunction through thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma. High renal tissue exposure during elimination contributes to nephrotoxicity risk.

Hepatic Elimination:

Minor role. Hepatic peptidases contribute to metabolism, but renal route dominates elimination.

5.5 Accumulation and Steady-State Kinetics

Accumulation with Daily Dosing:

With a 1-2 hour half-life, MT-II reaches steady-state rapidly. Drug accumulation occurs with repeated dosing when the dosing interval is shorter than four half-lives.

Time to Steady State:

• Calculation: Steady-state reached in ~4-5 half-lives
• MT-II: 4-5 × 1.5 hours = 6-8 hours
• Clinical Implication: After 2-3 doses (within 1-2 days), plasma levels stabilize

Accumulation Factor:

Minimal accumulation expected with once-daily dosing. With 24-hour dosing interval and 1.5-hour half-life:

• Half-lives between doses: 24 hours ÷ 1.5 hours = 16 half-lives
• Residual drug at next dose: (1/2)^16 = 0.0015% (essentially zero)

Clinical Interpretation:

Each daily dose of MT-II functions as a discrete pharmacokinetic event with negligible carryover to the next day. This explains:

• Rapid onset: Effects seen within 2-4 hours
• Daily dosing requirement: No accumulation; effects fade between doses
• Low tachyphylaxis risk (pharmacokinetic): Receptors fully "reset" between doses

Maintenance Dosing (Every 2-3 Days):

Once desired pigmentation achieved, dosing every 48-72 hours maintains melanin levels without continuous receptor stimulation. This approach:

• Minimizes receptor desensitization
• Reduces cumulative exposure
• Maintains tanning through melanin persistence (days to weeks)

5.6 Pharmacokinetic Variability

Factors Affecting MT-II Pharmacokinetics:

Renal Impairment:

MT-II can cause renal infarction and toxicity. Pre-existing kidney disease increases risk:

• eGFR >90 mL/min: Standard dosing with close monitoring
• eGFR 60-89 mL/min: Reduce dose by 25%; monitor creatinine weekly
• eGFR <60 mL/min: CONTRAINDICATION (risk of acute kidney injury)

Hepatic Impairment:

Minor impact expected (peptidase metabolism, not hepatic CYP450). However, liver disease may impair peptidase activity:

• Mild-Moderate Hepatic Impairment: No dose adjustment required; monitor liver enzymes
• Severe Hepatic Impairment (Child-Pugh C): Avoid MT-II (lack of safety data)

5.7 Pharmacokinetic-Pharmacodynamic (PK-PD) Relationship

Disconnect Between PK and PD:

MT-II exhibits prolonged pharmacodynamic effects despite short pharmacokinetic half-life:

Mechanism of PK-PD Disconnect:

1. Melanogenesis (Tanning):

   • MT-II activates MC1R → cAMP → MITF upregulation
   • Melanin synthesis continues for days after MT-II clearance
   • Melanin persistence: Weeks (turnover depends on keratinocyte shedding)
   • Effect: Long-lasting pigmentation despite short drug exposure

2. Sexual Arousal:

   • MC4R activation → oxytocin release → downstream signaling cascade
   • Receptor occupancy duration: 4-6 hours (longer than plasma half-life)
   • Signaling cascade persistence: 6-12 hours post-receptor activation

3. Appetite Suppression:

   • MC4R/MC3R hypothalamic activation → melanocortin signaling
   • Effect duration: 8-16 hours (outlasts plasma presence)

Clinical Implication:

Short pharmacokinetic half-life does NOT mean short effect duration. This allows:

• Once-daily dosing (for tanning/appetite suppression)
• As-needed dosing (for sexual function, 2-6 hours before activity)
• Maintenance dosing every 2-3 days (tanning preservation)

5.8 Pharmacokinetic Summary Table

Critical Pharmacokinetic Insight:

MT-II's short half-life combined with long effect duration is a double-edged sword:

• Advantage: Flexible dosing; minimal accumulation; rapid "on/off" control
• Disadvantage: Metabolic instability necessitates frequent dosing for sustained receptor activation (loading phase)

Safety Implication:

Rapid clearance does NOT mitigate toxicity risk. Cumulative exposure over weeks (loading phase) contributes to:

• Melanoma risk (chronic MC1R overstimulation)
• Rhabdomyolysis risk (mechanism unclear; possibly MC5R-mediated)
• Renal toxicity (high renal tissue exposure during elimination)

4. Age-Stratified Dosing and Physiological Considerations

MT-II pharmacokinetics and response vary significantly by age due to changes in body composition, receptor sensitivity, metabolic capacity, and baseline melanocyte activity. Age-specific safety concerns (particularly melanoma risk) become paramount in stratification.

4.1 Age 18-25: Young Adults

Physiological Context:

• Melanocyte Activity: Peak melanocyte responsiveness; most sensitive to MT-II
• Receptor Sensitivity: MC1R/MC4R receptors at maximal density and responsiveness
• Metabolic Capacity: Rapid peptide clearance; may require higher frequency dosing
• Baseline GH/IGF-1: Endogenous levels still elevated (sexual function effects may be less pronounced)
• Skin Health: Typically minimal UV damage; lower baseline melanoma risk but still significant with MT-II

Dosing Recommendations:

• Starting Dose: 0.25 mg (very conservative; assess tolerance)
• Therapeutic Dose Range: 0.5-0.75 mg (LOWER than older adults due to heightened receptor sensitivity)
• Loading Phase: 0.5 mg daily for 10-14 days
• Maintenance Phase: 0.5 mg every 3-4 days

Age-Specific Considerations:

• Higher Nausea Risk: Younger users report more intense nausea (possibly due to higher receptor sensitivity)
• Faster Pigmentation Response: Expect visible darkening within 3-5 doses (vs 5-7 doses in older adults)
• Spontaneous Erections: More frequent and more intense in this age group (can be disruptive)
• Risk Assessment: Cosmetic motivation often primary driver; ensure informed consent regarding melanoma risk

CRITICAL SAFETY CONCERN:

• Age <21: NOT RECOMMENDED (melanocyte development incomplete; long-term melanoma risk unknown)
• Consider long-term cumulative melanoma risk over remaining lifespan (50+ years)

4.2 Age 26-35: Peak Adult Years

Physiological Context:

• Melanocyte Activity: Still robust but beginning gradual decline
• Receptor Sensitivity: Near-optimal MC1R/MC4R function
• Metabolic Capacity: Efficient peptide clearance
• Body Composition: Typically lean to moderate body fat; distribution volume considerations
• Baseline Melanoma Risk: Cumulative UV exposure beginning to manifest

Dosing Recommendations:

• Starting Dose: 0.25-0.5 mg (assess tolerance)
• Therapeutic Dose Range: 0.75-1.0 mg
• Loading Phase: 0.75 mg daily for 10-14 days
• Maintenance Phase: 0.75-1.0 mg every 2-3 days

Age-Specific Considerations:

• Balanced Response: Expect reliable tanning and sexual enhancement effects
• Nausea Tolerance: Generally better than younger adults; still require conservative titration
• Sexual Function: Peak effectiveness for libido enhancement in this age range
• Body Composition Goals: Often combining with training and nutrition protocols

Monitoring Priorities:

• Full-body skin examination BEFORE starting (document all existing moles)
• Monthly self-checks of all moles
• Professional dermatology exam every 6 months during use

4.3 Age 36-50: Periandropausal/Perimenopausal Years

Physiological Context:

• Melanocyte Activity: Moderate decline; slower pigmentation response expected
• Receptor Sensitivity: Beginning subtle decline in MC receptor density
• Metabolic Capacity: Slower peptide clearance; longer half-life implications
• Body Composition: Increasing body fat percentage (affects distribution volume)
• Hormonal Changes: Declining testosterone (men), estrogen fluctuation (women)
• Cumulative UV Damage: Significant; melanoma risk elevated vs younger cohorts

Dosing Recommendations:

• Starting Dose: 0.5 mg (more conservative due to slower clearance)
• Therapeutic Dose Range: 0.75-1.25 mg
• Loading Phase: 0.75-1.0 mg daily for 14-21 days (longer loading due to slower melanocyte response)
• Maintenance Phase: 1.0 mg every 2-3 days

Age-Specific Considerations:

• Slower Pigmentation Onset: May require 7-10 doses for visible darkening (vs 3-5 in younger adults)
• Increased Fat Mass: Higher volume of distribution; may require slightly higher doses for equivalent effect
• Sexual Function Enhancement: Often primary motivation in this age group (age-related libido decline)
• Nausea Profile: Generally better tolerance than younger adults

Monitoring Priorities:

• CRITICAL: Professional skin examination MANDATORY before starting (high cumulative UV exposure)
• Track all existing moles with photography
• Monthly self-checks; professional exam every 3-4 months during use
• Consider bloodwork: CK (creatine kinase) to monitor rhabdomyolysis risk

4.4 Age 51-65: Post-Menopausal/Andropausal Years

Physiological Context:

• Melanocyte Activity: Significant decline; melanocyte density reduced
• Receptor Sensitivity: Moderate MC receptor downregulation
• Metabolic Capacity: Reduced hepatic/renal clearance; extended half-life
• Body Composition: Higher body fat percentage; reduced lean mass
• Hormonal Status: Post-menopausal (women), low testosterone (men)
• Cumulative UV Damage: Very high; melanoma risk significantly elevated
• Cardiovascular Health: Increased prevalence of hypertension, atherosclerosis

Dosing Recommendations:

• Starting Dose: 0.5 mg (assess tolerance and clearance)
• Therapeutic Dose Range: 1.0-1.5 mg (higher than younger adults due to reduced receptor sensitivity)
• Loading Phase: 1.0 mg daily for 21-28 days (extended loading required)
• Maintenance Phase: 1.0-1.25 mg every 2 days

Age-Specific Considerations:

• Much Slower Pigmentation: Expect 10-14 doses for visible results
• Reduced Sexual Function Response: MC4R-mediated libido enhancement may be blunted; realistic expectation management critical
• Medication Interactions: High prevalence of concurrent medications (see Drug Interactions section)
• Kidney Function: Age-related GFR decline; monitor creatinine and BUN

Monitoring Priorities:

• ABSOLUTE REQUIREMENT: Full dermatological assessment before starting
• High-risk population for melanoma; consider whether risk-benefit justifies use
• Professional skin exam every 3 months during use
• Quarterly bloodwork: CK, creatinine, BUN, liver enzymes
• Blood pressure monitoring (flushing can exacerbate hypertension)

STRONG CONSIDERATION: For individuals >60 with significant sun damage history, personal/family melanoma history, or >10 moles: AVOID MT-II ENTIRELY. Risk-benefit ratio heavily skewed toward risk.

4.5 Age 65+: Geriatric Population

Physiological Context:

• Melanocyte Activity: Substantial decline; very slow pigmentation
• Receptor Sensitivity: Significant MC receptor downregulation
• Metabolic Capacity: Markedly reduced clearance (hepatic and renal)
• Polypharmacy: High likelihood of multiple concurrent medications
• Cardiovascular Disease: High prevalence; MT-II effects on BP and HR concerning
• Cumulative UV Damage: Lifetime exposure; very high melanoma risk

Dosing Recommendations:

• GENERAL RECOMMENDATION: AVOID MT-II in this population
• If absolutely proceeding despite risk:
  • Starting Dose: 0.25 mg (extended observation period)
  • Therapeutic Dose Range: 0.75-1.25 mg (highly individualized)
  • Loading Phase: 0.75 mg daily for 28+ days
  • Maintenance Phase: 0.75-1.0 mg every 2-3 days

Age-Specific Considerations:

• Very Limited Pigmentation Response: Melanocyte density so reduced that therapeutic effect may be minimal
• High Adverse Event Risk: Kidney dysfunction, cardiovascular events, drug interactions
• Melanoma Risk: HIGHEST OF ALL AGE GROUPS - lifetime UV exposure, immunosenescence

CRITICAL ASSESSMENT: The risk-benefit ratio for MT-II in adults >65 is highly unfavorable. Melanoma risk is unacceptably high. Physiological response to MT-II is blunted. Safer alternatives (spray tans, topical DHA) strongly preferred.

4.6 Age-Stratified Summary Table

5. Sex-Specific Considerations

MT-II exhibits significant sex-specific differences in both pharmacokinetics and pharmacodynamics due to differences in body composition, hormonal milieu, receptor distribution, and clinical endpoints.

5.1 Male-Specific Pharmacology

Body Composition Impact:

• Higher Lean Body Mass: Average male 70-80 kg (larger distribution volume)
• Lower Body Fat Percentage: Typically 15-25% (affects SC absorption and distribution)
• Dosing Implication: Higher absolute doses required for equivalent plasma concentration

Hormonal Context:

• Testosterone Levels: Endogenous testosterone may modulate MC4R sensitivity
• Age-Related Decline: Testosterone declines ~1% per year after age 30; sexual function effects of MT-II may be more pronounced in older men

Sexual Function - Male-Specific Mechanism:

Erection Pathway:

1. MT-II crosses blood-brain barrier (lipophilic cyclic peptide)
2. Activates MC4R in paraventricular nucleus (PVN) of hypothalamus
3. Stimulates oxytocin-releasing neurons
4. Oxytocin projects to spinal cord (sacral segments S2-S4)
5. Activates parasympathetic outflow to penile arteries
6. Nitric oxide (NO) release → cGMP → smooth muscle relaxation → erection

Clinical Evidence (Male):

• Double-blind crossover (N=20 men): 17/20 (85%) achieved erection at 0.025 mg/kg
• Effective for psychogenic ED (CNS-mediated pathway intact)
• Effective for organic ED (neural pathway bypasses some vascular limitations)
• Onset: 2-6 hours post-injection
• Duration: 6-12 hours
• Dose-Response: Higher doses (1.0-1.5 mg) produce more reliable erections but increased nausea

Spontaneous Erections - Management:

• Frequency: Common to very common (10-30% of doses)
• Timing: Typically 2-4 hours post-injection
• Duration: Usually <1 hour (self-limiting)
• Clinical Significance: Usually not problematic; can be disruptive in social/work settings
• When to Seek Emergency Care: Erection lasting >4 hours (priapism) - MEDICAL EMERGENCY

Priapism Risk (Male-Specific):

• Definition: Painful erection lasting >4 hours
• Mechanism: MC4R overstimulation → prolonged parasympathetic activation → ischemic priapism
• Incidence with MT-II: Unknown (case reports exist but no systematic data)
• Risk Factors: Sickle cell disease, leukemia, multiple myeloma, history of priapism, concurrent PDE5 inhibitor use
• Management: IMMEDIATE emergency medical care (aspiration, phenylephrine injection)
• Prevention: Start with low doses (0.5 mg); avoid combining with PDE5 inhibitors

Male Dosing for Sexual Enhancement:

• Body Weight <70 kg: 0.5-1.0 mg as-needed
• Body Weight 70-85 kg: 0.75-1.25 mg as-needed
• Body Weight >85 kg: 1.0-1.5 mg as-needed
• Timing: 2-6 hours before anticipated sexual activity
• Frequency: Maximum 2-3x per week (minimize tachyphylaxis)

5.2 Female-Specific Pharmacology

CRITICAL DATA LIMITATION: The vast majority of MT-II clinical trials EXCLUDED WOMEN. Female-specific dosing and safety data are largely extrapolated from male studies or derived from anecdotal reports. No controlled trials specifically evaluate MT-II in women for sexual dysfunction.

Body Composition Impact:

• Lower Lean Body Mass: Average female 55-70 kg (smaller distribution volume)
• Higher Body Fat Percentage: Typically 25-35% (affects SC absorption and distribution)
• Dosing Implication: Lower absolute doses required; higher fat percentage may prolong absorption

Hormonal Context:

• Estrogen/Progesterone Cycling: MC4R sensitivity may vary across menstrual cycle
  • Follicular Phase (Days 1-14): Higher estrogen may enhance MC4R responsiveness
  • Luteal Phase (Days 15-28): Progesterone may blunt MC4R activation
• Menopause: Declining estrogen; unclear impact on MT-II response
• Oral Contraceptives: Synthetic estrogen/progesterone may alter MC receptor sensitivity (no data)

Sexual Function - Female-Specific Mechanism:

Arousal Pathway (Theoretical - No Direct Clinical Evidence):

1. MT-II activates MC4R in hypothalamus (same as men)
2. Hypothalamic activation increases oxytocin release
3. Oxytocin enhances subjective sexual desire (libido)
4. Parasympathetic activation increases vaginal blood flow
5. Increased genital blood flow → vaginal lubrication, clitoral engorgement

Clinical Evidence (Female):

• NO controlled trials in women for sexual dysfunction
• Anecdotal reports suggest:
  • Enhanced libido (subjective desire)
  • Increased genital arousal (engorgement, lubrication)
  • Variable response (highly individual)
  • Similar nausea profile to men

Female Arousal - Measurement Challenge: Unlike male erection (objective, measurable endpoint), female arousal is primarily subjective. This makes clinical trial design difficult and contributes to lack of female-specific data.

Female Dosing for Sexual Enhancement (EXTRAPOLATED):

• Body Weight <55 kg: 0.25-0.5 mg as-needed
• Body Weight 55-70 kg: 0.25-0.75 mg as-needed
• Body Weight >70 kg: 0.5-1.0 mg as-needed
• Timing: 2-6 hours before anticipated sexual activity
• Frequency: Maximum 2-3x per week (minimize tachyphylaxis)

Female-Specific Considerations:

• Start Lower: Women generally more sensitive to peptides; start at 0.25 mg
• Cycle Phase: Consider timing around follicular phase (higher estrogen may enhance effect)
• Menstrual Irregularities: Unknown whether MT-II affects menstrual cycle; monitor for changes
• Contraception: Maintain reliable contraception (pregnancy effects unknown)

Pregnancy and Breastfeeding:

• Pregnancy: ABSOLUTE CONTRAINDICATION - no safety data; theoretical risk to fetal melanocyte development
• Breastfeeding: CONTRAINDICATION - unknown whether MT-II passes into breast milk; theoretical infant risk

5.3 Tanning Response - Sex Differences

Melanocyte Activity:

• Baseline Melanin: Women typically have slightly more melanin than men (estrogen effect on melanocytes)
• UV Response: Women often tan more readily naturally (estrogen enhances melanocyte activity)
• MT-II Response: Women may achieve equivalent pigmentation at slightly lower doses

Tanning Dosing (Sex-Specific):

• Men (70-85 kg): 0.75-1.0 mg daily (loading), 1.0 mg every 2-3 days (maintenance)
• Women (55-70 kg): 0.5-0.75 mg daily (loading), 0.75 mg every 2-3 days (maintenance)

Pigmentation Pattern:

• Women: May develop more even pigmentation (estrogen effect)
• Men: May develop patchier pigmentation initially

5.4 Side Effect Profile - Sex Differences

Nausea:

• Incidence: Similar between sexes (~38% of injections in both)
• Severity: Women report slightly higher nausea severity in some anecdotal reports (may be reporting bias)
• Management: Same strategies (empty stomach, antihistamine, bedtime dosing)

Flushing:

• Incidence: Women may experience more intense facial flushing (estrogen-mediated vasodilation)
• Duration: 2-4 hours post-injection in both sexes

Cardiovascular Effects:

• Blood Pressure: Women may have greater BP variability (hormonal cycle influences BP regulation)
• Heart Rate: Similar tachycardia risk in both sexes

Melanoma Risk:

• Baseline Risk: Women have slightly LOWER melanoma incidence than men
• MT-II Risk: Theoretical risk applies equally to both sexes (MC1R overstimulation pathway)

5.5 Sex-Specific Summary Table

6. Comprehensive Drug Interactions

MT-II is metabolized by peptidases (not hepatic CYP450 enzymes), which limits traditional drug-drug interactions. However, pharmacodynamic interactions (effects on shared physiological pathways) are significant and potentially serious.

6.1 Cardiovascular Medications

Alpha-Blockers (Doxazosin, Prazosin, Terazosin, Tamsulosin)

Interaction Mechanism:

• MT-II → MC4R activation → central sympathetic modulation → vasodilation
• Alpha-blockers → peripheral α1-adrenergic blockade → vasodilation
• Combined effect: Additive vasodilation → hypotension risk

Clinical Significance: MODERATE TO HIGH

• Risk of orthostatic hypotension (dizziness, syncope)
• Risk of reflex tachycardia

Management:

• Preferred: Avoid concurrent use
• If concurrent use necessary:
  • Monitor blood pressure closely
  • Start MT-II at lowest dose (0.25 mg)
  • Advise patient to rise slowly from sitting/lying
  • Time doses separately (e.g., alpha-blocker morning, MT-II evening)

ACE Inhibitors (Lisinopril, Enalapril) and ARBs (Losartan, Valsartan)

Interaction Mechanism:

• MT-II causes mild vasodilation and occasional BP changes
• ACE-I/ARBs lower blood pressure via RAAS inhibition
• Combined effect: Possible additive hypotension (less pronounced than alpha-blockers)

Clinical Significance: LOW TO MODERATE

• Generally well-tolerated combination
• Monitor for symptomatic hypotension

Management:

• No dose adjustment typically required
• Monitor BP if starting MT-II while on ACE-I/ARB
• Advise patient to report dizziness or lightheadedness

Beta-Blockers (Metoprolol, Atenolol, Propranolol)

Interaction Mechanism:

• No direct interaction
• MT-II may cause reflex tachycardia (flushing, vasodilation)
• Beta-blockers blunt tachycardia response

Clinical Significance: LOW

• Beta-blocker may mask MT-II-induced tachycardia
• No dosing adjustment needed

Statins (Atorvastatin, Simvastatin, Rosuvastatin)

Interaction Mechanism:

• CRITICAL CONCERN: Both MT-II and statins can cause rhabdomyolysis
• MT-II → melanocortin receptor effects on muscle (mechanism unclear)
• Statins → inhibit HMG-CoA reductase → impaired muscle cell membrane integrity
• Combined effect: Potentially synergistic rhabdomyolysis risk

Clinical Significance: HIGH

• Risk of severe muscle breakdown
• Can lead to acute kidney injury

Management:

• CAUTION STRONGLY ADVISED
• If combining:
  • Baseline CK (creatine kinase) level
  • Monitor CK weekly for first month, then monthly
  • Patient education: STOP immediately if muscle pain, weakness, dark urine
  • Consider temporarily holding statin during MT-II cycle (discuss with prescriber)

6.2 Diabetes Medications

Insulin (All Types)

Interaction Mechanism:

• MT-II → MC4R activation → appetite suppression → reduced food intake
• Reduced food intake + same insulin dose → hypoglycemia risk

Clinical Significance: MODERATE TO HIGH

• Risk of severe hypoglycemia if insulin not adjusted

Management:

• CRITICAL: Patients on insulin MUST monitor blood glucose closely
• Reduce mealtime insulin by 10-20% when initiating MT-II
• Titrate insulin based on actual food intake
• Continuous glucose monitoring (CGM) strongly recommended
• Patient education: recognize hypoglycemia symptoms (shakiness, sweating, confusion)

Metformin

Interaction Mechanism:

• MT-II → appetite suppression → reduced caloric intake
• Metformin → reduces hepatic glucose production, improves insulin sensitivity
• Combined effect: Potential for enhanced glycemic control

Clinical Significance: LOW

• Generally synergistic for glycemic control
• Minimal hypoglycemia risk (metformin alone rarely causes hypoglycemia)

Management:

• Monitor blood glucose
• May see improved glucose control; metformin dose adjustment rarely needed

GLP-1 Agonists (Semaglutide, Tirzepatide, Liraglutide)

Interaction Mechanism:

• GLP-1 agonists → strong appetite suppression, delayed gastric emptying
• MT-II → mild to moderate appetite suppression
• Combined effect: Synergistic appetite suppression

Clinical Significance: MODERATE

• Excessive appetite suppression may lead to inadequate protein/nutrient intake
• Risk of muscle loss during weight loss

Management:

• NOT RECOMMENDED to combine for appetite suppression (GLP-1 alone superior)
• If using MT-II for tanning while on GLP-1: monitor protein intake carefully (target 1.6-2.2 g/kg to preserve lean mass)
• Watch for excessive weight loss

SGLT2 Inhibitors (Empagliflozin, Canagliflozin)

Interaction Mechanism:

• No direct interaction
• Both promote modest weight loss via different mechanisms

Clinical Significance: LOW

• Safe to combine

6.3 Psychiatric Medications

SSRIs (Fluoxetine, Sertraline, Escitalopram)

Interaction Mechanism:

• SSRIs → increase serotonin → can INHIBIT sexual function (anorgasmia, reduced libido)
• MT-II → MC4R activation → ENHANCES libido and sexual function
• Effect: Potentially offsetting (MT-II may counteract SSRI-induced sexual dysfunction)

Clinical Significance: LOW TO MODERATE (Potentially Beneficial)

• MT-II may ameliorate SSRI-induced sexual dysfunction

Case Reports/Anecdotal Evidence:

• Some users report MT-II restores sexual function impaired by SSRIs
• No controlled trials evaluating this combination

Management:

• Safe to combine from drug interaction perspective
• May provide sexual function benefit
• Monitor for serotonin syndrome (theoretical; no documented cases): agitation, hyperthermia, tachycardia

SNRIs (Venlafaxine, Duloxetine)

Interaction Mechanism:

• Similar to SSRIs (sexual dysfunction from serotonin increase)
• SNRIs also increase norepinephrine → possible CV effects

Clinical Significance: LOW TO MODERATE

• MT-II may counteract SNRI-induced sexual dysfunction
• Monitor blood pressure (both can affect BP)

Bupropion (Wellbutrin)

Interaction Mechanism:

• Bupropion → dopamine/norepinephrine reuptake inhibition → LESS sexual dysfunction than SSRIs
• MT-II → enhances libido
• Combined effect: Potentially synergistic for sexual function

Clinical Significance: LOW (Potentially Synergistic)

• Safe combination
• May enhance sexual function effects

Benzodiazepines (Alprazolam, Clonazepam, Diazepam)

Interaction Mechanism:

• No direct pharmacological interaction
• Benzos → CNS depression
• MT-II → no CNS depression

Clinical Significance: LOW

• Safe to combine

Stimulants (Amphetamine, Methylphenidate, Modafinil)

Interaction Mechanism:

• Stimulants → increase norepinephrine/dopamine → appetite suppression, tachycardia
• MT-II → MC4R → appetite suppression, possible tachycardia
• Combined effect: Additive appetite suppression, additive cardiovascular stimulation

Clinical Significance: MODERATE

• Excessive appetite suppression
• Tachycardia risk

Management:

• Monitor heart rate and blood pressure
• Ensure adequate caloric and protein intake
• Consider separating doses (stimulant morning, MT-II evening)

6.4 Pain and Anti-Inflammatory Medications

NSAIDs (Ibuprofen, Naproxen, Celecoxib)

Interaction Mechanism:

• NSAIDs → COX inhibition → renal prostaglandin synthesis impaired → renal perfusion reduced
• MT-II → (rare) rhabdomyolysis → myoglobin release → acute kidney injury
• Combined effect: If rhabdomyolysis occurs, NSAIDs may worsen kidney injury

Clinical Significance: MODERATE

• NSAIDs alone not a problem
• IF rhabdomyolysis occurs, concurrent NSAID use worsens renal outcome

Management:

• Safe to use NSAIDs during MT-II use
• IF muscle pain develops: STOP MT-II, STOP NSAIDs, check CK and creatinine immediately

Opioids (Oxycodone, Hydrocodone, Tramadol)

Interaction Mechanism:

• Opioids → mu-opioid receptor agonism → nausea, constipation
• MT-II → nausea (38% incidence)
• Combined effect: Additive nausea

Clinical Significance: LOW TO MODERATE

• Increased nausea burden

Management:

• Antiemetic prophylaxis if combining (ondansetron, metoclopramide)
• Consider separating doses

Corticosteroids (Prednisone, Dexamethasone)

Interaction Mechanism:

• Corticosteroids → appetite stimulation, fluid retention, hyperglycemia
• MT-II → appetite suppression, mild tanning, possible glucose effects
• Combined effect: Opposing appetite effects (corticosteroid likely dominant)

Clinical Significance: LOW

• MT-II appetite suppression unlikely to overcome corticosteroid-induced hunger
• No safety concern

6.5 Thyroid Medications

Levothyroxine (Synthroid)

Interaction Mechanism:

• No direct interaction
• Both affect metabolic rate (thyroid via T3/T4, MT-II minimally via MC4R)

Clinical Significance: LOW

• Safe to combine
• No dose adjustment needed

Management:

• Monitor TSH per usual (typically every 6-12 months)

6.6 Peptide and Anabolic Interactions

Growth Hormone Secretagogues (CJC-1295, Ipamorelin, MK-677)

Interaction Mechanism:

• No direct interaction
• Both are peptides; no shared metabolic pathways

Clinical Significance: LOW

• Safe to combine

Practical Consideration:

• Many users combine MT-II (for tanning) with GH peptides (for body composition)
• No documented adverse interactions

Testosterone Replacement Therapy (TRT)

Interaction Mechanism:

• TRT → exogenous testosterone → may enhance libido independently
• MT-II → MC4R-mediated libido enhancement
• Combined effect: Potentially synergistic for sexual function

Clinical Significance: LOW (Potentially Synergistic)

• Safe to combine
• May enhance sexual function more than either alone

Management:

• Monitor hematocrit (TRT increases RBC production; dehydration from MT-II nausea could concentrate blood)
• Ensure adequate hydration

BPC-157, TB-500 (Healing Peptides)

Interaction Mechanism:

• No direct interaction
• Different mechanisms (BPC-157 = angiogenesis, TB-500 = actin regulation; MT-II = melanocortin receptors)

Clinical Significance: LOW

• Safe to combine

Practical Consideration:

• Common to use MT-II concurrently with healing peptides
• No documented adverse interactions

6.7 Supplements

Caffeine

Interaction Mechanism:

• Caffeine → CNS stimulation, mild appetite suppression, tachycardia
• MT-II → appetite suppression, possible tachycardia
• Combined effect: Additive stimulatory effects

Clinical Significance: LOW

• Generally safe
• Monitor for excessive heart rate if sensitive to stimulants

Yohimbine

Interaction Mechanism:

• Yohimbine → alpha-2 adrenergic antagonist → increases norepinephrine → enhances lipolysis, arousal
• MT-II → MC4R → arousal, appetite suppression
• Combined effect: Potentially synergistic for sexual function and fat loss

Clinical Significance: LOW TO MODERATE

• Additive stimulatory effects (anxiety, tachycardia risk)

Management:

• Start with low dose of yohimbine (5 mg) if combining
• Monitor heart rate and anxiety levels

Melatonin

Interaction Mechanism:

• Melatonin → melanin precursor; regulates circadian rhythm
• MT-II → melanin production via MC1R
• Effect: No direct interaction (different pathways)

Clinical Significance: LOW

• Safe to combine
• Many users take MT-II before bed and use melatonin for sleep

5-HTP

Interaction Mechanism:

• 5-HTP → serotonin precursor
• MT-II → no serotonergic activity
• Combined effect: No direct interaction

Clinical Significance: LOW

• Safe to combine

6.8 Alcohol

Interaction Mechanism:

• Alcohol → vasodilation, GI irritation, nausea, dehydration
• MT-II → vasodilation (flushing), nausea, possible dehydration
• Combined effect: Additive nausea, flushing, dehydration

Clinical Significance: MODERATE

• Significantly worsened nausea if combining
• Enhanced flushing

Management:

• AVOID alcohol within 6-8 hours of MT-II injection (minimize nausea)
• If drinking while on MT-II maintenance protocol: ensure excellent hydration

6.9 Drug Interaction Summary Table

7. Pharmacokinetics

Half-Life

Short Plasma Half-Life: Enhanced in vivo stability with T₁/₂: 1-2 hours.

Consistent Literature: Relatively short half-life of MT-II: approximately 2 hours.

Conflicting Data: One source reports ~33 hours, but scientific literature more consistently supports 1-2 hour range.

Bioavailability

Subcutaneous Bioavailability: Data from related Melanotan I shows SC dose completely bioavailable compared to IV dose.

Oral Bioavailability: No detectable drug levels observed following oral dosing (Melanotan I data).

Implication: SC injection required for therapeutic effect; oral administration ineffective.

Pharmacokinetic Limitations

Limited Clinical Data: Melanotan II has never successfully completed clinical trials, limiting comprehensive human PK data.

8. Bloodwork Monitoring and Safety Surveillance

Given MT-II's serious safety profile (melanoma, rhabdomyolysis, systemic toxicity), comprehensive monitoring is MANDATORY for anyone using this compound. This section outlines required baseline testing, on-treatment monitoring, and interpretation frameworks.

8.1 Pre-Treatment Baseline Assessment

CRITICAL REQUIREMENT: All baseline testing MUST be completed BEFORE first MT-II dose.

Dermatological Assessment (ABSOLUTE PRIORITY):

• Full-body skin examination by board-certified dermatologist
• Photographic documentation of ALL existing moles (baseline reference)
• Dermoscopic evaluation of any atypical lesions
• Mole count: If >10 moles total OR any dysplastic nevi → CONTRAINDICATION
• Personal history assessment: Any prior melanoma or non-melanoma skin cancer → ABSOLUTE CONTRAINDICATION
• Family history assessment: First-degree relatives with melanoma → STRONG CONTRAINDICATION

Laboratory Baseline Panel:

Optional but Recommended:

• Testosterone (total and free) - if using MT-II for sexual function (establish baseline libido context)
• LDH (Lactate Dehydrogenase) - additional rhabdomyolysis marker
• Myoglobin (urine) - sensitive early marker of muscle breakdown

8.2 On-Treatment Monitoring Schedule

Dermatological Monitoring (HIGHEST PRIORITY):

Laboratory Monitoring:

First Month (High-Risk Period):

Months 2-3:

• CK, Creatinine, BUN: Every 2 weeks
• Continue frequent monitoring during loading phase

Maintenance Phase (After Month 3):

• CK, Creatinine, BUN: Monthly
• AST, ALT: Every 3 months (monitor liver function)
• CBC: Every 3 months (monitor hematological status)
• Fasting Glucose: Every 3 months (track metabolic effects)

Cardiovascular Monitoring:

• Blood Pressure: Weekly for first month (flushing can transiently elevate BP)
• Heart Rate: Monitor if on concurrent stimulants or alpha-blockers

8.3 Expected vs Concerning Lab Changes

Expected Changes (Normal MT-II Physiology):

Concerning Changes (Require Action):

8.4 Rhabdomyolysis - Early Detection and Management

CRITICAL SAFETY CONCERN: Rhabdomyolysis is a documented serious adverse event with MT-II. Early detection is life-saving.

Classic Triad of Rhabdomyolysis:

1. Muscle Pain: Severe myalgia (often thighs, calves, lower back)
2. Weakness: Difficulty walking, climbing stairs
3. Dark Urine: Cola-colored or tea-colored (myoglobin in urine)

Laboratory Diagnosis:

IMMEDIATE MANAGEMENT IF RHABDOMYOLYSIS SUSPECTED:

1. STOP MT-II immediately (do not administer any further doses)
2. STOP any statins (if applicable - synergistic muscle toxicity)
3. STOP NSAIDs (worsen kidney injury)
4. Seek URGENT medical care (emergency department)
5. Aggressive IV hydration (medical treatment - saline infusion to prevent kidney failure)
6. Monitor electrolytes (hyperkalemia life-threatening)

Prevention Strategies:

• Baseline CK before starting
• Weekly CK monitoring first month
• Educate patient: muscle pain = STOP immediately
• Avoid combining with statins if possible
• Ensure excellent hydration

8.5 Melanoma Surveillance - Dermatological Monitoring Protocol

HIGHEST PRIORITY MONITORING for MT-II users.

Self-Examination Protocol (Weekly):

ABCDE Rule for Melanoma Detection:

• A = Asymmetry: One half of mole doesn't match the other
• B = Border Irregularity: Edges ragged, notched, or blurred
• C = Color Variation: Multiple colors (tan, brown, black, red, white, blue)
• D = Diameter: >6 mm (pencil eraser size) OR growing
• E = Evolving: Changing in size, shape, color, or symptoms (itching, bleeding)

Self-Exam Technique:

1. Full-Body Inspection: Use full-length mirror + hand mirror for back, scalp
2. Partner Assistance: Have partner check back, scalp, posterior areas
3. Photography: Take monthly photos of any questionable moles for comparison
4. Documentation: Log any new moles or changes

Professional Dermatology Exam:

• Baseline: Full-body skin mapping with photography
• Monthly (First 3 Months): Track new moles, measure existing moles
• Every 3 Months (Maintenance): Ongoing surveillance
• Dermoscopy: For any atypical lesions
• Biopsy: LOW THRESHOLD for biopsy of any changing or concerning mole

RED FLAGS - Seek IMMEDIATE Dermatology Evaluation:

• Any mole changing size, shape, or color
• New mole appearing (especially if irregular)
• Mole bleeding or crusting
• Mole itching or painful
• Mole developing irregular borders

STOP MT-II Immediately If:

• Any concerning mole changes detected
• Dermatologist recommends discontinuation
• Biopsy reveals dysplastic nevus or melanoma

8.6 Marker-Based Dosing Adjustments

Unlike many peptides, MT-II dosing is NOT typically adjusted based on bloodwork markers (no IGF-1 titration like GH peptides). However, certain lab findings require dose modification or discontinuation.

CK-Based Dosing:

Kidney Function-Based Dosing:

Concurrent Medication Adjustments:

8.7 Monitoring Summary Table

CRITICAL TAKEAWAY: MT-II is a HIGH-RISK compound. Monitoring is NOT optional—it is MANDATORY for safe use. The two most critical surveillance areas are:

1. Dermatological monitoring (melanoma risk)
2. CK monitoring (rhabdomyolysis risk)

Failure to monitor appropriately can result in life-threatening consequences.

9. Dosing Protocols

Phase I Clinical Trial Dosing

1996 Single-Blind Study (N=3 males):

• Starting Dose: 0.01 mg/kg
• Escalation: 0.005 mg/kg increments
• Final Doses: 0.03 mg/kg (2 subjects), 0.025 mg/kg (1 subject)
• Administration: SC injections daily (Monday-Friday) for 2 weeks
• Recommendation: 0.025 mg/kg/day for future Phase I studies

Erectile Dysfunction Study Dosing

Psychogenic & Organic ED (N=20 men):

• Dose: 0.025 mg/kg
• Result: Penile erection in 17 of 20 men
• Conclusion: "Melanotan-II is potent initiator of erections with manageable side effects at 0.025 mg/kg"
• Caveat: 12.9% had severe nausea at this dose

Tanning Protocol (Research/Anecdotal)

Clinical Trial Evidence: Early human trials identified 1-2 mg daily doses for tanning, with conservative protocols starting lower to minimize nausea/flushing.

Minimal Effective Protocol: 5 low doses every other day by SC injection demonstrated tanning activity.

Body Weight-Based Dosing Protocol (SOP - Research Reference Only)

Step 1: Calculate Weight-Based Starting Dose

Clinical trials used 0.025 mg/kg as the effective dose. This translates to:

Step 2: Loading Phase (If Pursuing Tanning)

Step 3: Maintenance Phase

After achieving desired pigmentation (typically 2-4 weeks):

• Reduce to 0.5-1.0 mg every 2-3 days
• Combine with moderate UV exposure
• Pigmentation persists 4-8 weeks post-discontinuation

Step 4: Managing Side Effects

Nausea Mitigation:

• Start at lowest dose (0.25-0.5 mg)
• Inject before bed (sleep through nausea)
• Antihistamines 30 min prior may help
• Avoid fatty meals before injection

Flushing:

• Usually peaks at 2-4 hours post-injection
• Antihistamines may reduce
• Subsides with repeated dosing

Step 5: Required Monitoring

Before Starting:

• Full-body skin examination by dermatologist
• Document all existing moles (photographs)

During Use:

• Weekly self-examination of all moles
• Note any changes in size, shape, color, borders
• STOP immediately if any mole changes detected

Step 6: STOP Immediately If:

• Any mole changes (size, shape, color, bleeding)
• New moles appearing
• Priapism (erection >4 hours) - MEDICAL EMERGENCY
• Severe nausea/vomiting
• Muscle pain (rhabdomyolysis risk)
• Decreased urine output
• Vision changes

Reconstitution:

• 10 mg vial + 2 mL bacteriostatic water = 5 mg/mL
• 1 mL = 5 mg; 0.1 mL (10 units) = 0.5 mg
• Refrigerate after reconstitution; use within 30 days

6. Clinical Research & Evidence

Phase I Safety Trial (1996)

Pilot Study (N=3):

• Single-blind, placebo-controlled
• Dose escalation: 0.01 → 0.025-0.03 mg/kg
• Safety: Mild nausea at most dose levels, not requiring antiemetic
• Result: Recommended dose 0.025 mg/kg/day

Tanning Efficacy Study

Human UV Radiation Study: Effects of superpotent melanotropic peptide in combination with solar UV radiation on tanning demonstrated enhanced pigmentation.

Erectile Dysfunction Studies

Double-Blind Crossover (N=20):

• Population: Men with psychogenic and organic ED
• Dose: 0.025 mg/kg
• Result: 17/20 (85%) achieved penile erection
• Side Effects: Manageable at this dose

Systemic Toxicity Case Report

2012 Case Report: MT-II injection resulting in systemic toxicity and rhabdomyolysis. Patient presented with sympathomimetic excess, rhabdomyolysis, and renal dysfunction.

Clinical Trial Failure

Never Successfully Completed Trials: Melanotan II has never successfully completed clinical trials, preventing FDA approval pathway.

7. Safety Profile

Skin Cancer Risk: Most concerning side effect is risk of serious skin cancers. Change in mole shape, new moles, skin cancer have occurred, especially in light-skinned individuals.

Rhabdomyolysis: Dangerous syndrome where muscle breaks down and releases proteins into bloodstream that damage kidneys. Case report documented systemic toxicity with rhabdomyolysis and renal dysfunction.

Kidney Dysfunction & Brain Swelling: Reports of kidney dysfunction and swelling of the brain with MT-II use.

Priapism: Painful erection that does not go away and can damage penis, requiring emergency treatment.

Vision Loss, Stroke, Anaphylaxis: Potential loss of vision, muscle tremors, stroke and anaphylaxis reported.

Common Side Effects

High Incidence GI Effects:

• Nausea: 38% of injections
  • Severe nausea: 15.3%
  • ~70% of users experience nausea
• Vomiting
• Stomach cramps
• Decreased appetite

Additional Common Effects:

• Flushing
• Tiredness
• Yawning
• Darkened skin
• Spontaneous erections
• Headache

Dermatologic Effects: Increased moles and freckles, darkening of existing moles.

Regulatory Agency Safety Warnings

FDA Warning: FDA warns against using Melanotan II. FDA cautions consumers about injecting substances not FDA-approved without licensed healthcare provider oversight.

TGA Warning (Australia): Don't risk using tanning products containing melanotan.

HPRA Warning (Ireland): Reminder of serious health risks with Melanotan 2 self-tan products.

Overall Safety Classification

WebMD Assessment: Melanotan is POSSIBLY UNSAFE when given as a shot.

8. Administration & Practical Application

Route: Subcutaneous injection (oral ineffective) Sites: Abdomen, thigh (rotate sites) Reconstitution: Bacteriostatic water for lyophilized powder

Injection Protocol (Research Data Only)

• Reconstitute lyophilized powder
• Use insulin syringes
• Inject SC slowly
• Rotate injection sites
• Administer on empty stomach (may reduce nausea)

Nausea Management: Given 70% nausea rate, research subjects often required:

• Empty stomach administration
• Lower starting doses
• Gradual titration
• Antiemetic pre-medication in some cases

Monitoring Required:

• Skin changes (new moles, changing moles)
• Kidney function (creatinine, BUN)
• Muscle pain (rhabdomyolysis warning)
• Persistent erections (priapism emergency)
• Vision changes

9. Storage & Stability

Lyophilized Powder:

• Store at -20°C (freezer) long-term
• 2-8°C (refrigerator) short-term
• Protect from light and moisture

Reconstituted Solution:

• Refrigerate 2-8°C immediately
• Use within 14-30 days
• Do NOT freeze
• Protect from light

Stability Note: 1-2 hour half-life requires proper storage to maintain potency.

11. Product Cross-Reference

Core Peptides Equivalent: Product page returned ethical refusal to provide details due to MT-II being unapproved substance with serious safety concerns.

Epiq Aminos: NOT RECOMMENDED - MT-II is illegal to sell/market for human use in US and many other jurisdictions.

Black Market Reality: Despite regulatory prohibition, MT-II available through:

• Unregulated online vendors
• "Research chemical" suppliers
• Underground sources
• Serious health risks amplified by impure product

Safer Alternatives:

• FDA-approved afamelanotide (Scenesse) for erythropoietic protoporphyria
• Spray tanning
• Sunless tanning lotions (dihydroxyacetone)
• Sun protection strategies

PT-141 (Bremelanotide): For sexual dysfunction: FDA-approved alternative (Vyleesi) derived from MT-II but selective MC4R agonist with better safety profile.

Clinical Insights - Practitioner Dosing

Source: YouTube practitioner interviews

• based on how you're experiencing it. When I first started with Thyin Alpha 1, the PA told me to do 50 units three days a week, right.
• to help me get through it. Y but then I started doing the baby doses every day. So I do 25 units on a buck 10, . But my doctor, Dr. Haley Toddson with Optimize Health.

Stacking Insights

• Hi everyone and welcome back to the Faster Way podcast. I am so excited to be here with my new friend Jay Campbell who is a hormone optimization authority.
• t, AIDS was a death sentence, acquired immune deficiency syndrome.

12. References & Citations

1. Melanotan II - Wikipedia
2. Hadley ME, et al. Evaluation of Melanotan-II in pilot phase-I clinical study. Life Sci. 1996.
3. Wessells H, et al. Melanocortin receptor agonists, penile erection, sexual motivation: Melanotan II. Int J Impot Res. 2000.
4. PubChem - Melanotan-II (CID 92432)
5. WebMD - Melanotan Overview
6. TGA - Don't Risk Using Tanning Products Containing Melanotan
7. UNSW - What is Melanotan-II TGA Urges Consumers to Avoid
8. HPRA - Serious Health Risks with Melanotan 2
9. FDA Notice of Opportunity for Hearing - Manookian
10. Drug Topics - FDA Issues Warning Letter to Melanocorp
11. Levine MS, et al. MT-II injection resulting in systemic toxicity. Clin Toxicol. 2012.
12. Peptide Society - Melanotan II Monograph

Document Version: 1.0 Last Updated: December 23, 2025 Development Status: Failed Clinical Trials Regulatory Status: NOT FDA-APPROVED - ILLEGAL TO SELL/MARKET IN US - BANNED IN MULTIPLE COUNTRIES